ASH News Daily 2013 - Day 3 - (Page A-1)

Read this issue online at www.hematology.org/ashnewsdaily2013_monday Follow us on Twitter using #ASH13 SCHEDULE 9:00 - 10:00 a.m. E. Donnall Thomas Lecture Title: Sailing to Ithaka: Gene Therapy's Odyssey from Investigational Agent to Therapeutic Product Speaker: Katherine A. High, MD Hall F, Convention Center 10:30 a.m. - 12:00 noon Spotlight Sessions (ticketed sessions) Various locations in the convention center 12:15 - 1:15 p.m. ASH Choosing Wisely® List Room 243-245, Convention Center 12:15 - 1:15 p.m. Featured Topic: Chimeric Antigen Receptors (CAR): Driving Immunotherapy! Room E3, Convention Center 1:30 - 2:30 p.m. Ernest Beutler Lecture and Prize Title: Thrombopoietin: From Molecule to Medicine Speakers: Kenneth Kaushansky, MD, and David J. Kuter, MD, DPhil Hall F, Convention Center 2:45 - 4:15 p.m. Spotlight Sessions (ticketed sessions) Various locations in the convention center 6:00 - 8:00 p.m. Poster Hall Reception Hall E & G, Convention Center Chemoimmunotherapy: The Key to Open the Door for Elderly CLL Patients Plus Chlorambucil (Clb) Versus Rituximab Plus Clb in Patients with Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical BY ANITA RAJASEKHAR, MD, MS, AND MARC ZUMBERG, MD T he treatment of elderly patients with chronic lymphocytic leukemia (CLL) is an important topic of investigation given that the median age of newly diagnosed CLL patients is 72 years. Elderly patients are often excluded from clinical trials due to comorbidities that compromise their ability to tolerate aggressive treatments. For frail, elderly patients with CLL who are unable to tolerate intense therapies, no currently available therapies are superior to standard chlorambucil (Clb) monotherapy. However, the closed door to this unmet treatment need may now be unlocked by the novel glycoengineered type II CD20 antibody, obinutuzumab (GA101). In the Plenary abstract, "Head-to-Head Comparison of Obinutuzumab (GA101) BY CAROLINE CROMWELL, MD adequate and appropriate blood cell production to be continued over a lifetime. This system of checks and balances must run like a well-oiled machine. Many of the parts that keep this machine running remain a mystery. Overall, the stem cell population is maintained at a steady state. Somatic cells must be able to self-renew as well as to W IN THIS SECTION B-Cell Lymphoma A-2 Program Updates A-4 Beutler Lecture A-5 Sports Medicine A-6 Sickle Cell Disease A-16 Don't miss the Featured Topic: Chimeric Antigen Receptors (CAR): Driving Immunotherapy! Session today at 12:15 p.m. in E3 (located inside Hall E) in the convention center. ithin the bone marrow, a fine balance must be maintained in order for Conditions (Comorbidities): Final Stage 2 Results of the CLL11 Trial," »» CLL Page A-16 ASH President Dr. Janis Abkowitz provides an overview of Sunday's Plenary Scientific Session. Keeping "Mom" Well Behaved differentiate. Cells must also have cues to remain at rest, or quiescent. Otherwise uncontrolled growth can occur. Within the bone marrow regulation of the stem cell pool occurs through the existence of microenvi- roments or niches. In yesterday's Plenary Scientific presentation titled "Megakaryocytes Regulate Hematopoietic Stem »» STEM CELLS Page A-17 Sue Van, President of the Wallace H. Coulter Foundation, presents ASH President Dr. Janis L. Abkowitz a check for $5 million. This endowment will provide funding to enable ASH to continue to develop innovative programs that continue Coulter's legacy. http://www.hematology.org/ashnewsdaily2013_monday

Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 3

Table of Contents

ASH News Daily 2013 - Day 3

http://www.nxtbookMEDIA.com